Dynavax: MVC Begins Phase 1 Trial For Adjuvanted Vaccine Candidate To Prevent COVID-19

(RTTNews) – Medigen Vaccine Biologics Corp. and Dynavax Technologies Corp. (DVAX) announced that MVC has obtained a Taiwan government subsidy for successfully initiating a phase 1 clinical trial in Taiwan. The grant was earmarked by the government for purposes of research and development of a locally produced COVID-19 vaccine. The subsidy will be released at agreed upon milestones in the total amount of up to $16.4 million.

The first participant in phase 1 clinical trial was dosed with MVC’s COVID-19 vaccine combined with Dynavax’s CpG 1018 adjuvant in early October.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article